Abeona Therapeutics Management
Management criteria checks 2/4
Abeona Therapeutics' CEO is Vish Seshadri, appointed in Oct 2021, has a tenure of 3.58 years. total yearly compensation is $3.51M, comprised of 17.5% salary and 82.5% bonuses, including company stock and options. directly owns 2.79% of the company’s shares, worth €7.85M. The average tenure of the management team and the board of directors is 3.6 years and 4.2 years respectively.
Key information
Vish Seshadri
Chief executive officer
US$3.5m
Total compensation
| CEO salary percentage | 17.55% |
| CEO tenure | 3.6yrs |
| CEO ownership | 2.8% |
| Management average tenure | 3.6yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$44m |
| Dec 31 2024 | US$4m | US$615k | -US$64m |
| Sep 30 2024 | n/a | n/a | -US$71m |
| Jun 30 2024 | n/a | n/a | -US$53m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$3m | US$555k | -US$54m |
| Sep 30 2023 | n/a | n/a | -US$45m |
| Jun 30 2023 | n/a | n/a | -US$39m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$1m | US$505k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$83m |
| Jun 30 2022 | n/a | n/a | -US$84m |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$2m | US$255k | -US$85m |
Compensation vs Market: Vish's total compensation ($USD3.51M) is above average for companies of similar size in the German market ($USD817.73K).
Compensation vs Earnings: Vish's compensation has increased whilst the company is unprofitable.
CEO
Vish Seshadri (48 yo)
Dr. Vishwas Seshadri, also known as Vish, Ph.D. & M.B.A., serves as Chief Executive Officer, President and Director at Abeona Therapeutics Inc. since October 15, 2021. He served as the Senior Vice Presiden...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$3.51m | 2.79% € 7.9m | |
| Chief Financial Officer | 3.2yrs | US$1.63m | 1.05% € 2.9m | |
| Chief Legal Officer | 5.1yrs | US$1.27m | 0.80% € 2.3m | |
| Senior VP | 3.9yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief People Officer | 3.3yrs | no data | no data | |
| VP & Head of Quality | 3.6yrs | no data | no data | |
| Senior VP | 1.7yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | no data | no data | no data |
Experienced Management: PCJ's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$3.51m | 2.79% € 7.9m | |
| Independent Director | 4.2yrs | US$246.05k | 0.19% € 535.4k | |
| Independent Director | 4.2yrs | US$246.05k | 0.31% € 867.9k | |
| Independent Director | 4.1yrs | US$246.05k | 0.31% € 872.4k | |
| Independent Director | less than a year | US$74.23k | 0.097% € 273.1k | |
| Independent Director | 5.2yrs | US$234.88k | 0.28% € 773.7k | |
| Independent Director | 4.1yrs | US$249.80k | 0.32% € 894.1k | |
| Member of Scientific Advisory Board | 8.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.1yrs | no data | no data | |
| Chairman of the Board | 4.2yrs | US$261.05k | 0.37% € 1.0m |
Experienced Board: PCJ's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 15:44 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abeona Therapeutics Inc. is covered by 25 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| George Zavoico | B. Riley Securities, Inc. |
| Elemer Piros | Cantor Fitzgerald & Co. |